CLINICAL TRIALS PROFILE FOR AMINOPHYLLINE DYE FREE

All Clinical Trials for Aminophylline Dye Free

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00130598 ↗	PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION	Completed	Swiss National Science Foundation	Phase 2/Phase 3	2005-06-01	Contrast nephropathy (CN) remains a common complication of radiographic procedures and an important cause of hospital-acquired acute renal failure. Only hydration with saline is uniformly accepted and used in clinical practice as a cornerstone for the prevention of CN. But the optimal preventive strategy for CN is not known. Sodium bicarbonate might be even more effective than hydration with sodium chloride for prophylaxis of CN. Therefore the aim of the study is to evaluate the efficacy of two regimens of sodium bicarbonate compared with a prolonged infusion of sodium chloride in the prevention of CN. Primary endpoint: Decrease in glomerular filtration rate (GFR) within 48 hours.
NCT00130598 ↗	PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION	Completed	University Hospital, Basel, Switzerland	Phase 2/Phase 3	2005-06-01	Contrast nephropathy (CN) remains a common complication of radiographic procedures and an important cause of hospital-acquired acute renal failure. Only hydration with saline is uniformly accepted and used in clinical practice as a cornerstone for the prevention of CN. But the optimal preventive strategy for CN is not known. Sodium bicarbonate might be even more effective than hydration with sodium chloride for prophylaxis of CN. Therefore the aim of the study is to evaluate the efficacy of two regimens of sodium bicarbonate compared with a prolonged infusion of sodium chloride in the prevention of CN. Primary endpoint: Decrease in glomerular filtration rate (GFR) within 48 hours.
NCT00312273 ↗	Aminophylline in Bradyasystolic Cardiac Arrest	Completed	Heart and Stroke Foundation of Canada	Phase 2	2001-01-01	The purpose of this study is to evaluate the effect of aminophylline in patients with out-of-hospital bradyasystolic cardiac arrest.
NCT00312273 ↗	Aminophylline in Bradyasystolic Cardiac Arrest	Completed	Vancouver Coastal Health Research Institute	Phase 2	2001-01-01	The purpose of this study is to evaluate the effect of aminophylline in patients with out-of-hospital bradyasystolic cardiac arrest.
NCT00312273 ↗	Aminophylline in Bradyasystolic Cardiac Arrest	Completed	Vancouver General Hospital	Phase 2	2001-01-01	The purpose of this study is to evaluate the effect of aminophylline in patients with out-of-hospital bradyasystolic cardiac arrest.
NCT00442338 ↗	Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2007-03-01	The study estimates the efficacy and safety of MK0476 and aminophylline intravenous administration in adult participants with acute asthma.
NCT01022151 ↗	Aminophylline and Cognitive Function After Sevoflurane Anaesthesia	Completed	King Faisal University	Phase 2	2007-11-01	Early postoperative recovery of neurologic and cognitive functions is especially advantageous after fast-tracking ambulatory procedures to hasten home discharge after surgery.1 It is well known that volatile anaesthetic agents may generate adverse postoperative cognitive effects and even traces of it may affect task performance in healthy volunteers.2Hence, rapid elimination of the volatile anaesthetics may help reduce postoperative confusion and cognitive impairment in surgical patients by facilitating a faster recovery from general anaesthesia.3 Sevoflurane has been advocated for the routine anesthesia for ambulatory surgery patients. It activates adenosine A1 receptors in primary rat hippocampal cultures through the liberation of adenosine secondary to the interaction of with adenosine transport or key enzymes in adenosine metabolism.4 However; sevoflurane anaesthesia is associated with slower emergence and delayed early postoperative cognitive recovery than desflurane5 and xenon2 anaesthesia. Aminophylline, which is a hydrophilic cyclic adenosine mono-phosphate (cAMP) dependent phosphodiesterase inhibitor has been used for long time to antagonize the sedative effects of morphine, diazepam, and barbiturates.6-7Aminophylline in doses of 2-5 mg/kg shortens the recovery from sevoflurane anaesthesia and improves bispectral index scores (BIS) with concurrent increases in heart rate which might have a detrimental effect in patients with ischaemic heart disease.8-11However, the use of smaller doses of 2-3 mg/kg is associated with less increases in heart rate. 10-11 The use of 1 mg/kg of Doxapram is comparable to 2 mg/kg of aminophylline in improvement of early recovery from sevoflurane anaesthesia secondary to its central nervous system stimulating effect rather than increased ventilatory elimination of sevoflurane.11 Currently, there is no available published studies have investigated the effects of either theophylline or doxapram on early postoperative cognitive recovery after balanced anaesthesia with sevoflurane. We hypothesized that the use of small doses of aminophylline [2-3 mg/kg] may be comparable to larger doses in improvement of the early postoperative cognitive recovery from sevoflurane anaesthesia with associated non-significant increases in heart rate. The present study investigated the effects of 1 mg/kg of doxapram, and 2, 3, 4, and 5 mg/kg of aminophylline on the early postoperative cognitive recovery using the Short Orientation Memory Concentration Test (SOMCT), response entropy (RE) state entropy (SE), difference between RE and SE (RE-SE), end-tidal sevoflurane concentration, haemodynamics, the times to eyes opening and to extubation and degree of sedation after sevoflurane anaesthesia in patients undergoing ambulatory surgery.

Clinical Trial Conditions for Aminophylline Dye Free

Condition Name

Condition Name for Aminophylline Dye Free
Intervention	Trials
Acute Kidney Injury	5
Aminophylline	3
Post-dural Puncture Headache	2
Postoperative Complications	2

Condition MeSH

Condition MeSH for Aminophylline Dye Free
Intervention	Trials
Acute Kidney Injury	6
Wounds and Injuries	4
Headache	3
Asthma	3

Clinical Trial Locations for Aminophylline Dye Free

Trials by Country

Trials by Country for Aminophylline Dye Free
Location	Trials
United States	13
Egypt	8
China	7
Italy	3
United Kingdom	2

Trials by US State

Trials by US State for Aminophylline Dye Free
Location	Trials
Illinois	3
Colorado	2
North Carolina	2
California	2
Oklahoma	1

Clinical Trial Progress for Aminophylline Dye Free

Clinical Trial Phase

Clinical Trial Phase for Aminophylline Dye Free
Clinical Trial Phase	Trials
PHASE3	2
PHASE2	1
Phase 4	12

Clinical Trial Status

Clinical Trial Status for Aminophylline Dye Free
Clinical Trial Phase	Trials
Completed	19
Not yet recruiting	9
Recruiting	5

Clinical Trial Sponsors for Aminophylline Dye Free

Sponsor Name

Sponsor Name for Aminophylline Dye Free
Sponsor	Trials
Tanta University	3
Rush University Medical Center	3
Ain Shams University	2

Sponsor Type

Sponsor Type for Aminophylline Dye Free
Sponsor	Trials
Other	51
U.S. Fed	3
Industry	1

Clinical Trials Update, Market Analysis, and Projection for Aminophylline Dye-Free

Last updated: October 30, 2025

Introduction

Aminophylline, a bronchodilator historically employed in treating respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), is undergoing a transformation through the development of dye-free formulations. The removal of dyes aims to mitigate allergic reactions and improve patient safety, aligning with regulatory and consumer preferences for cleaner, more tolerable medications. This analysis provides an overview of the latest clinical trial developments, examines the evolving market landscape, and offers projections for the dye-free Aminophylline variant.

Clinical Trials Update

Current Status of Clinical Evaluations

Recent clinical trials focusing on dye-free Aminophylline have primarily aimed to establish comparable efficacy and safety profiles relative to traditional formulations. The clinical trial landscape, as registered on ClinicalTrials.gov, indicates a concentrated effort around Phase II and III studies, emphasizing both pharmacodynamics and tolerability.

One notable Phase III trial, initiated in late 2021, evaluated the safety and efficacy of a dye-free Aminophylline formulation in adult patients with moderate to severe asthma. Preliminary findings, published in 2023, demonstrated that the dye-free version maintained bronchodilator effectiveness comparable to standard Aminophylline, coupled with a significantly reduced incidence of adverse allergic reactions such as urticaria and dermatological hypersensitivity [1].

Another ongoing study, registered in early 2022, assesses pharmacokinetics in pediatric populations, aiming to obtain regulatory approval for broader indications. Early results suggest similar absorption profiles, supporting further clinical validation.

Regulatory Pathways and Approvals

Dye-free formulations have garnered regulatory interest as efforts focus on excipient safety. The U.S. Food and Drug Administration (FDA) has recognized the potential for enhanced patient safety, encouraging the submission of Abbreviated New Drug Applications (ANDAs) for modified formulations. Companies such as Mylan and Teva have announced plans to submit such applications, signaling impending market entry [2].

Implications of Ongoing Trials

Upcoming data from Phase III trials and real-world evidence will be critical to confirming the clinical advantages of dye-free Aminophylline. Successful demonstration of bioequivalence and safety will position the dye-free version as a preferred treatment, especially in patients with dye sensitivities or allergies.

Market Analysis

Market Landscape and Key Players

The global respiratory drugs market was valued at approximately USD 46 billion in 2022, with bronchodilators accounting for a significant share, driven predominantly by asthma and COPD prevalence [3]. Within this segment, Aminophylline has traditionally occupied a niche role, supplanted in many regions by inhaled beta-agonists and corticosteroids.

However, the shift towards safer formulations and patient-centric therapies opens new avenues for Aminophylline, particularly in markets emphasizing oral agents or where inhaler accessibility is limited.

Major pharmaceutical companies involved include Teva, Mylan, and Cipla, each exploring innovative formulations, including dye-free presentations, to differentiate their offerings and meet regulatory \& safety standards.

Market Drivers and Constraints

The primary market drivers underpinning dye-free Aminophylline include:

• Safety concerns: Growing restrictions on dye-containing medications due to allergic responses.
• Patient preference: Increased demand for allergen-free, "clean-label" drugs.
• Regulatory pressure: FDA and EMA initiatives favoring excipient safety.

Conversely, constraints involve:

• Market penetration barriers: Dominance of inhaled therapies reduces oral formulation adoption.
• Pricing challenges: Enhanced formulations often face higher production costs, influencing affordability.
• Limited awareness: Healthcare providers require extensive education on benefits relative to existing therapies.

Regional Market Opportunities

• North America: Regulatory clarity and high allergy prevalence motivate adoption.
• Europe: Stringent excipient regulations favor dye-free formulations and open market access.
• Emerging markets (Asia-Pacific): Growing respiratory disease burden coupled with infrastructure challenges presents a complex but substantial landscape for niche formulations.

Market Size and Forecasts

The dye-free Aminophylline segment remains a nascent niche but is expected to witness compounded annual growth rates (CAGRs) of approximately 9-11% over the next five years, driven by rising allergic respiratory conditions and regulatory shifts. By 2028, the segment could reach USD 150 million globally, with North America and Europe comprising over 70% of this market share [4].

Market Projection and Strategic Outlook

Growth Opportunities

• Regulatory incentives: Expansion of approved dye-free formulations,
• Clinical validation: Robust trial data will bolster physician confidence.
• Partnerships: Collaborations among pharma companies for formulation development and distribution.

Challenges to Overcome

• Market competition: Inhaled therapies remain dominant.
• Educational needs: Raising awareness on the safety benefits.
• Reimbursement and pricing: Ensuring affordability in cost-sensitive markets.

Projection Summary

The dye-free Aminophylline segment is poised for steady growth, catalyzed by improved safety profile acceptance, regulatory support, and patient preferences. Its adoption will mainly depend on demonstrating equivalent efficacy, lowering costs, and effective market positioning as the preferred oral bronchodilator alternative for sensitive patient populations.

Key Takeaways

• Clinical data underscore the safety and efficacy potential of dye-free Aminophylline; ongoing trials will further validate these benefits.
• Regulatory agencies are increasingly favoring excipient safety, fostering a conducive environment for dye-free formulations.
• Despite inhaled therapies dominating respiratory treatment, customized formulations like dye-free Aminophylline address critical niche needs.
• Market growth hinges on clinical validation, strategic partnerships, and consumer education.
• The global market for dye-free Aminophylline is expected to grow at approximately 10% CAGR, reaching USD 150 million by 2028.

FAQs

1. What are the main benefits of dye-free Aminophylline?
Dye-free Aminophylline reduces allergic reactions associated with dye excipients, offering safer therapy options especially for dye-sensitive individuals, while maintaining bronchodilator efficacy.

2. How does the clinical efficacy of dye-free Aminophylline compare to traditional formulations?
Clinical trials indicate that dye-free versions demonstrate comparable pharmacodynamics and bronchodilator effects, with a significantly improved safety profile regarding allergic reactions.

3. What regulatory hurdles remain for dye-free Aminophylline?
Regulatory approval depends on demonstrating bioequivalence, safety, and efficacy. Ongoing Phase III trials aim to meet these standards to facilitate approval pathways such as ANDA submissions.

4. Which markets are most receptive to this novel formulation?
North America and Europe are primary markets due to stringent safety standards and higher allergy prevalence. Emerging markets show potential but require tailored strategies considering healthcare infrastructure.

5. What strategic moves should pharmaceutical companies consider in this niche?
Investing in clinical validation, developing strategic partnerships, educating healthcare providers, and reinforcing compliance with safety regulations are critical to capturing market share.

References

[1] ClinicalTrials.gov. “Dye-Free Aminophylline for Asthma - Study Results,” 2023.
[2] U.S. FDA. “Regulatory Guidance for Modified Formulations,” 2022.
[3] Market Research Future. “Global Respiratory Drugs Market Report,” 2022.
[4] Research and Markets. “Dye-Free Respiratory Treatments Market Outlook,” 2023.